PDS Biotechnology Corporation (PDSB)
Market Cap | 108.20M |
Revenue (ttm) | n/a |
Net Income (ttm) | -43.89M |
Shares Out | 36.68M |
EPS (ttm) | -1.37 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 725,437 |
Open | 3.000 |
Previous Close | 3.030 |
Day's Range | 2.800 - 3.010 |
52-Week Range | 2.530 - 6.850 |
Beta | 1.82 |
Analysts | Strong Buy |
Price Target | 16.67 (+465.09%) |
Earnings Date | Aug 12, 2024 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunolog... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is $16.67, which is an increase of 465.09% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/t/n/press5-2431861.jpg)
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
![](https://cdn.snapi.dev/images/v1/z/a/press13-2422987.jpg)
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (...
![](https://cdn.snapi.dev/images/v1/9/y/conf7-2414472.jpg)
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
![](https://cdn.snapi.dev/images/v1/d/z/press10-2408870.jpg)
PDS Biotechnology Announces Details of Virtual KOL Event
Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 Virtual Webinar Updated ...
![](https://cdn.snapi.dev/images/v1/i/w/press12-2405834.jpg)
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
![](https://cdn.snapi.dev/images/v1/k/8/press19-2385124.jpg)
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial
![](https://cdn.snapi.dev/images/v1/m/k/press9-2343617.jpg)
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
Unique mechanism of action of the combination of PDS01ADC and Versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial
![](https://cdn.snapi.dev/images/v1/u/m/conf6-2332870.jpg)
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline ...
![](https://cdn.snapi.dev/images/v1/b/c/press3-2321936.jpg)
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
Preclinical research published in Vaccines demonstrates Infectimune ® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants
![](https://cdn.snapi.dev/images/v1/3/f/press13-2239230.jpg)
PDS Biotech Announces Retirement of Lauren V. Wood, M.D.
Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company Board-certified oncologist and hemat...
![](https://cdn.snapi.dev/images/v1/d/c/press9-2230240.jpg)
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline o...
![](https://cdn.snapi.dev/images/v1/8/m/press15-2182767.jpg)
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeline of ta...
![](https://cdn.snapi.dev/images/v1/a/z/press14-2173614.jpg)
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline o...
![](https://cdn.snapi.dev/images/v1/t/r/press17-2156571.jpg)
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
PRINCETON, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline o...
![](https://cdn.snapi.dev/images/v1/0/d/press3-2149523.jpg)
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline o...
![](https://cdn.snapi.dev/images/v1/x/3/conf20-2143758.jpg)
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of ta...
![](https://cdn.snapi.dev/images/v1/m/e/press5-2114999.jpg)
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
PRINCETON, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of ta...
![](https://cdn.snapi.dev/images/v1/7/x/press17-2098474.jpg)
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of ta...
![](https://cdn.snapi.dev/images/v1/k/t/press14-2087191.jpg)
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)
PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of ta...
![](https://cdn.snapi.dev/images/v1/b/k/press12-2085558.jpg)
PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of ta...
![](https://cdn.snapi.dev/images/v1/j/a/conf17-2077651.jpg)
PDS Biotech to Present at the LD Micro Main Event XVI
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of t...
![](https://cdn.snapi.dev/images/v1/f/e/press5-2076063.jpg)
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of t...
![](https://cdn.snapi.dev/images/v1/w/s/conf11-2071786.jpg)
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of t...
![](https://cdn.snapi.dev/images/v1/p/7/press13-2070752.jpg)
PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of t...
![](https://cdn.snapi.dev/images/v1/i/t/press8-2061287.jpg)
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023
Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA® Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA®